Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, hair follicle transcriptomic responses to a 10-day HIIT program revealed both existing and new biomarkers, such as certain miRNAs, offering a potentially effective way to monitor cellular and molecular HIIT adaptations.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study identified key proteins, such as Sfrp1 and Ppard, involved in the complex and dynamic regulation of yak hair follicle growth and degeneration across different stages, offering insights into yaks' adaptation to highland environments.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This review discusses factors affecting hair health, types of alopecia, and the potential of phytochemicals in managing hair loss but reports no new clinical results; it highlights the need for further studies.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This review highlights the potential of natural compounds like terpenoids, flavonoids, and polyphenols in promoting hair regrowth for those with alopecia areata by activating growth pathways and modulating immune responses, but calls for further research to confirm their therapeutic utility.

This study suggests that phytochemicals from natural sources could be safer alternatives to conventional treatments for hair loss, as they may activate key pathways involved in hair growth.

This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

Leflunomide is more likely to help treat alopecia areata than cause it.

This meeting synopsis on the 66th Annual Montagna Symposium reports no new results but outlines discussions on precision dermatology, integrating molecular insights with clinical applications for personalized skin care.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

This review discusses current and emerging treatments for discoid lupus erythematosus, suggesting that new biologic and small-molecule therapies may improve disease control when combined with traditional management.

This study concluded that advancements in understanding the immunological mechanisms of alopecia areata have led to promising therapies, particularly JAK inhibitors and novel drug delivery systems, but further research is needed for clinical application.

This review highlights that a comprehensive approach combining pharmacological, immunomodulatory, and regenerative interventions, including phototherapy enhanced with topical treatments and JAK inhibitors, appears effective and promising in the management of vitiligo by addressing its autoimmune and melanocyte-loss aspects.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

This review describes various T-cell-mediated alopecias characterized by distinct lymphocytic patterns and explores their pathophysiology. It highlights the role of CD8+ and regulatory T cells, the JAK/STAT pathway, and stem cell niches, contributing to understanding and potentially addressing these hair loss conditions.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.